PetVivo Holdings, Inc. Files 10-Q for Period Ending December 31, 2023

TL;DR

<b>PetVivo Holdings, Inc. filed its Q3 2024 10-Q report on February 12, 2024, detailing financial performance for the period ending December 31, 2023.</b>

AI Summary

PetVivo Holdings, Inc. (PETVW) filed a Quarterly Report (10-Q) with the SEC on February 12, 2024. PetVivo Holdings, Inc. filed a 10-Q for the period ending December 31, 2023. The filing covers the third quarter of the fiscal year ending March 31, 2024. The company's fiscal year end is March 31. The filing was made on February 12, 2024. The company's principal business is in Surgical & Medical Instruments & Apparatus.

Why It Matters

For investors and stakeholders tracking PetVivo Holdings, Inc., this filing contains several important signals. This 10-Q filing provides investors with an update on PetVivo's financial health and operational performance for the third quarter of its fiscal year. Understanding the details within this report is crucial for assessing the company's progress in the medical instruments and apparatus sector and its potential for future growth.

Risk Assessment

Risk Level: medium — PetVivo Holdings, Inc. shows moderate risk based on this filing. The company's financial performance and operational details are not yet fully elaborated in the provided text, requiring a deeper dive into the full filing to assess specific risks.

Analyst Insight

Review the full 10-Q filing to understand PetVivo's revenue, expenses, and any new developments impacting its market position.

Key Numbers

• 2023-12-31 — Reporting Period End Date (CONFORMED PERIOD OF REPORT)
• 2024-02-12 — Filing Date (FILED AS OF DATE)
• 0331 — Fiscal Year End (FISCAL YEAR END)
• 3841 — SIC Code (STANDARD INDUSTRIAL CLASSIFICATION)

Key Players & Entities

• PetVivo Holdings, Inc. (company) — FILER
• 20231231 (date) — CONFORMED PERIOD OF REPORT
• 20240212 (date) — FILED AS OF DATE
• 3841 (industry_code) — STANDARD INDUSTRIAL CLASSIFICATION
• NV (state) — STATE OF INCORPORATION
• 0331 (date) — FISCAL YEAR END
• 1934 Act (regulation) — SEC ACT
• 001-40715 (filing_id) — SEC FILE NUMBER

FAQ

Industry Context

PetVivo Holdings operates within the Surgical & Medical Instruments & Apparatus industry, a sector focused on the development and distribution of medical devices and equipment.

Regulatory Implications

As a publicly traded company, PetVivo Holdings is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of quarterly (10-Q) and annual (10-K) reports.

What Investors Should Do

1. Analyze the detailed financial statements within the 10-Q for revenue, net income, and cash flow.
2. Identify any new business developments, risks, or management changes disclosed in the filing.
3. Compare the current period's financial results with previous periods to assess performance trends.

Key Dates

• 2023-12-31: End of Reporting Period — Covers financial results for the quarter and year-to-date.
• 2024-02-12: Filing Date — Indicates when the 10-Q was submitted to the SEC.

Year-Over-Year Comparison

This is the first 10-Q filing provided for analysis in this session, so a direct comparison to a prior filing is not possible with the given data.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 PETV The Nasdaq Stock Market LLC

Filing Documents

• form10-q.htm (10-Q) — 1108KB
• ex10-1.htm (EX-10.1) — 89KB
• ex10-2.htm (EX-10.2) — 17KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 9KB
• 0001493152-24-005908.txt (&nbsp;) — 6518KB
• petv-20231231.xsd (EX-101.SCH) — 48KB
• petv-20231231_cal.xml (EX-101.CAL) — 59KB
• petv-20231231_def.xml (EX-101.DEF) — 206KB
• petv-20231231_lab.xml (EX-101.LAB) — 411KB
• petv-20231231_pre.xml (EX-101.PRE) — 315KB
• form10-q_htm.xml (XML) — 994KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3 Item 1.

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3. Qualitative and Quantitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 30

OTHER INFORMATION

PART II. OTHER INFORMATION 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosure 31 Item 5. Other information 31 Item 6. Exhibits 32

SIGNATURES

SIGNATURES 33 Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 Information included in this Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). This information may involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of PetVivo Holdings, Inc. (the "Company"), to be materially different from future results, performance, or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies, and expectations of the Company, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that the projections included in these forward-looking statements will come to pass. Actual results of the Company could differ materially from those expressed or implied in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" included in documents we file from time to time with the U.S. Securities and Exchange Commission (the "SEC'), including our Annual Report on Form 10-K for our fiscal year ended March 31, 2023, ("2023 10-K Report") and risks described in other SEC filings. Except as required by applicable laws, the Company has no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. 2 PART I. ITEM 1. FINANCIAL STATEMEN

Notes to Financial Statements

Notes to Financial Statements December 31, 2023 (Unaudited) NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment and/or management of afflictions and diseases in animals, initially for dogs and horses. The Company began commercialization of its lead product Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021. The Company has a pipeline of additional products for the treatment of animals in various stages of development. A portfolio of twenty patents protects the Company's biomaterials, products, production processes and methods of use. The Company's operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the "Company") was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in PetVivo, Inc. becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered

View Full Filing

View this 10-Q filing on SEC EDGAR